ESR1 and invasive breast carcinoma: Although based on the expression of estrogen receptor, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki67, the molecular classification of BrCa (luminal A, luminal B, HER2 positive and triple negative) has provided considerable benefits3, many patients with BrCa experience metastasis or recurrence.